series-b
Stage
2
Investors
About
Immusoft engineers patient-derived B cells to program them as plasma cells that produce therapeutic proteins, which are then infused back into patients to provide durable and personalized protein therapies.
Explore Immusoft's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.